See Other Indications
Patients HCPs
This site is for US Health Care Professionals only

Mechanism of Action

About Sandostatin LAR Depot

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension has been designed to target somatostatin receptors. Octreotide exerts pharmacologic actions similar to those of the natural hormone somatostatin, but it is an even more potent inhibitor of growth hormone, glucagon, and insulin.1,2 Once it presents in the systemic circulation, octreotide distributes and exhibits a 3-phase pharmacokinetic profile.2-4

 

COMPLEX MICROSPHERE TECHNOLOGY

Sandostatin LAR Depot allows for longer dosing intervals by using a complex microsphere technology. Drug particles are encapsulated within a biodegradable microsphere polymer matrix, which slowly biodegrades in the muscle.3,4

References: 1. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733-1742. 2. Sandostatin LAR Depot. Prescribing information. Novartis Pharmaceuticals Corp. 3. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin. 2009;12(12):2989-2999. 4. Petersen H, Bizec JC, Schuetz H, Delporte ML. Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide. BMC Res Notes. 2011;4(344):1-8.